Orteronel active as “switch” maintenance therapy after docetaxel chemotherapy

Posted on September 29, 2015 by Sitemaster

According to a presentation given at the European Cancer Congress, currently ongoing in Vienna, Austria, a small, recently completed Phase III trial has shown that orteronel (TAK-700) might have had some value in treatment of late stage prostate cancer after all. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 3 Comments »

Long-term use of abiraterone acetate at 250 mg/d: is this really viable?

Posted on February 6, 2012 by Sitemaster

It has been suggested that, after an initial “loading dose” for a period of time, abiraterone acetate could potentially be used to treat metastatic, castration-resistant prostate cancer (mCRPC) at a much lower daily maintenance dose than that currently approved. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , | 19 Comments »

  • Donate

  • Disclaimer

    News and information provided on this site should not be used for diagnosing or treating any health problem or disease.

    The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.

  • Hot Posts …

  • … and Archives